Complications of Amyloidosis


advertisement

About complications: Complications of Amyloidosis are secondary conditions, symptoms, or other disorders that are caused by Amyloidosis. In many cases the distinction between symptoms of Amyloidosis and complications of Amyloidosis is unclear or arbitrary.

Complications list for Amyloidosis: The list of complications that have been mentioned in various sources for Amyloidosis includes:

Complication statistics for Amyloidosis: The following are statistics from various sources about the complications of Amyloidosis:

  • Less than 15% of patients display the physical characteristics typically associated with amyloidosis i.e. enlargement of tongue, submandibular, swelling, and facial purpura in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • Less than 1% of patients with amyloidosis have tongue enlargement in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • In 33-40% of amyloidosis patients, the kidney is affected in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • There is echocardiographic evidence of amyloidosis in about 40% of patients in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • There is congestive heart failure due to amyloidosis in about 20% of patients in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • 1 in 6 amyloid patients have symptomatic liver involvement in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • Gastric mucosa biopsies reveal asymptomatic vascular amyloid deposits in 90% of patients with amyloidosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • Rectal biopsies reveal asymptomatic vascular amyloid deposits in 80% of patients with amyloidosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • 1% of patients with amyloidosis had symptomatic gastric amylodosis in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)
  • 6.5% of myeloid patients receiving melphalan eventually develop mylodysplasia in the US (Amyloidosis: Recognition, Prognosis and Conventional Therapy, American Society of Hematology)

Last revision: May 20, 2003

Medical Tools & Articles:


Next articles:

Medical Articles:
 
 
CureResearch.comTM Copyright © 2010 Health Grades, Inc. All rights reserved.
Home | Contents | Search | Site Map | Feedback | Contact Us | Terms of Use | Privacy Policy | About Us | Advertise